AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00689117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Gel (clindamycin )
Description: Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
Study NCT03867045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usability of an electronic symptom management application
Description: Usability of an electronic symptom management application in a pilot group of patients receiving cabozantinib for mRCC through data analytics and feedback from users
Study NCT03274921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biological determination
Description: Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients
Study NCT05008094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whole-exome sequencing
Description: Whole-exome sequencing with the focus on Parkinson's disease loci.
Study NCT05008094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota sequencing
Description: Next generation sequencing of microbiota from stool and saliva samples.
Study NCT00689117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin Gel (tretinoin)
Description: Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
Study NCT00689117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
Study NCT02204124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thunderbeat
Description: Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
Study NCT02204124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care scissors, ligatures, clips, and sutures
Study NCT00970385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP21
Description: CHOP regimen:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5.
Study NCT00970385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP/ABVD
Description: VIP regimen:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D
Study NCT00970385 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy consolidation
Description: The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
Study NCT00970385 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy consolidation
Description: The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
Study NCT03129399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope
Description: nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
Study NCT03129399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC video laryngoscope
Description: nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
Study NCT00081094 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 18F-Fluorodeoxyglucose-PET (FDG-PET)
Study NCT00081094 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 11Carbon-Acetate-PET
Study NCT01697410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
Study NCT01697410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
Study NCT02058524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Study NCT00988650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isocaloric diet
Study NCT00988650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric diet
Study NCT00988650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: free living conditions
Study NCT04176653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
Description: IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
Study NCT05008094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging of the brain focused on detection of free water in Substantia Nigra using a novel protocol.
Study NCT05008094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial ultrasound and Electroencephalography
Description: Transcranial ultrasound of Substantia Nigra, as well as high resolution EEG.
Study NCT04176653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
Description: IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
Study NCT02706990 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Physica KR
Description: Kinematic retaining total knee implant
Study NCT02706990 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Physica PS
Description: Posterior stabilized total knee implant
Study NCT03923244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OSDI survey
Description: Normal patient consultation schedule for cataract surgery with:~* Preoperative appointment scheduled for the patient~* Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~* Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~* An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~* Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
Study NCT00504946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone, lactose
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose
Study NCT05008094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA (Enzyme-Linked Immunosorbent Assay)
Description: ELISA (Enzyme-Linked Immunosorbent Assay) will be used to assess the inflammatory state, glial functions, and disease progression will also be determined through specific markers in the participant's serum and plasma samples
Study NCT05008094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescent correlation spectroscopy (FCS)
Description: Fluorescent correlation spectroscopy (FCS), more specifically, ThT fluctuating intensity fluorescent analysis (FIFA) will be used to determine the existence of pathological conformation protein forms and their relation to the disease's grade and therapy.
Study NCT00428675 — intervention group
Intervention type: OTHER
Intervention: ACI instrument
Description: Following ethics approval, 17 experts in symptom management assisted with content validation during the pilot phase. In the main study, participants complete the FACT-F, the POMS-Vsf, and the ACI Instrument. A research assistant collected demographic information and assigned an ECOG score.
Study NCT02063035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.
Study NCT02063035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single topical application of matching placebo, which is 100 mL of normal saline.
Study NCT03315351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Before it starts, a consultation will be done to collect patient's informations and disease history, a clinical exam will be done and an evaluation of radio-chemotherapy toxicity will be realized.~The brachytherapy include a pulsating flow treatment driven by RMI and CT-scan
Study NCT03315351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-scan
Description: The patient will undergo 2 PET-scan during the clinical trial:~* the first one is additional to the brachytherapy~* the second one is realized 4 months after the brachytherapy
Study NCT01756729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-100A
Description: Multiple four-week courses of continuous NovoTTF-100A treatment.
Study NCT01756729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A
Description: Multiple four-week courses of continuous NovoTTF-100A treatment.
Study NCT05659446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopy management of low output colonic fistula or leak after anterior resection for rectal cancer
Description: Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical \& mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
Study NCT00002520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Study NCT00002520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT04126382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubate-Surfactant-Extubate(INSURE)
Description: Infants are given an endotracheal intubation, with manual lung inflation in order to keep the oxygen supply，and the surfactant(kelisu,China Resources Shuanghe Pharmaceutical) was slowly instilled into the airway through the tracheal tube, and the tracheal tube was removed for non-invasive NCPAP(nasal continuous positive airway pressure)-assisted breathing.
Study NCT04126382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: less invasive surfactant administration(LISA)
Description: Infants are spontaneously breathing with nasal CPAP(continuous positive airway pressure) support without manual lung inflation and surfactant(kelisu,China Resources Shuanghe Pharmaceutical) is administered through vocal cords via a smaller catheter.
Study NCT04222751 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ankle Splint
Description: Ankle splint will be slightly modified from the commercial form to include a pneumatic air cell secured under the forefoot below the splint's padded lining. This replaces the foam wedge provided by the manufacturer, allowing a gradual adjustment of the forefoot/toe region.
Study NCT04222751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Splint
Description: Ankle splint will be slightly modified from the commercial form to include a pneumatic air cell secured under the forefoot below the splint's padded lining. This replaces the foam wedge provided by the manufacturer, allowing a gradual adjustment of the forefoot/toe region.
Study NCT00728221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: whole root in capsules (3g)
Study NCT00728221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (Panax ginseng)
Description: Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total ginsenoside fraction in capsules
Study NCT00728221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch
Description: Placebo
Study NCT00728221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (Panax Ginseng)
Description: Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total polysaccharide fraction (panaxans) in capsules
Study NCT00764556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
Study NCT04013594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate group
Description: Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery.
Study NCT00626743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SK3530 100mg, Placebo, Amlodipine
Study NCT00626743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK3530 100mg, Placebo, Amlodipine
Study NCT03074929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novel risk communication
Description: The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
Study NCT03891550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks for all HCV genotype patients with and without hepatic decompensation
Study NCT03907332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visits
Description: An experimental design, a cluster randomized controlled trial (RCT) will be used. A total of 20 clusters will be randomized with block randomization of electoral areas with a) resident staff midwives and b) resident Community Health Nurse midwifes. All women residing in an electoral area will receive the same intervention for practicality and to prevent contamination.
Study NCT02015169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: lapatinib 1250mg qd daily up to 8 cycles (3 weeks \* 8 cycles = 24 weeks)
Study NCT02808390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0507-34-Levo 80 mg
Description: GED-0507-34-Levo 80 mg BID for 8 Weeks
Study NCT02808390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0507-34-Levo 160 mg
Description: GED-0507-34-Levo 160 mg BID for 8 Weeks
Study NCT02808390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo BID for 8 Weeks
Study NCT01558063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.
Study NCT01558063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single infusion of saline given intravenously over 40 minutes.
Study NCT01558063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: 90-minute scan during the 40-minute infusion.
Study NCT01558063 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: 90-minute scan during the 40-minute infusion.
Study NCT00504946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone, colecalciferol, lactose
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose
Study NCT00504946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose
Study NCT03221894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: GRAPE granules
Description: GRAPE granules was mainly consisted of herbal medicines: Ren Shen (Ginseng, 10g/d), Di Huang (Rehmannia glutinosa, 30g/d), Shi Cangpu (Acorus tatarinowii, 10g/d), Yuan Zhi (Polygala tenuifolia, 10g/d), Yin Yanghuo (Epimedium brevicornu, 10g/d), Shan Zhuyu (Cornus officinalis, 10g/d), Rou Congrong (Cistanche deserticola, 10g/d), Yu Jin (Curcuma aromatica, 10g/d), Dan Shen (Salvia miltiorrhiza, 10g/d), Tian Ma (Angelica sinensis, 10g/d), Tian ma (Gastrodia elata, 10g/d), and Huang Lian (Berberine, 10g/d), which were supplied by Beijing Tcmages Pharmaceutical Co., LTD, Each bag of granules with 150ml warm water melt was taken orally twice a day.
Study NCT00508391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized interventricular delay biventricular pacing
Description: Lumax HF-T with optimized interventricular delay biventricular pacing
Study NCT05983289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653
Description: HSK7653 tablets in six doses beginning at 5 mg and rising to 150 mg
Study NCT05983289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tables in six doses beginning at 5 mg and rising to 150 mg
Study NCT03737162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent implantation of subclavian artery
Description: Stent implantation of subclavian artery
Study NCT03737162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent implantation of subclavian artery
Description: Stent implantation of subclavian artery
Study NCT00504946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children > 14 years old received 10mg oral tablet once daily at bedtime
Study NCT00504946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
Study NCT03557840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temocillin
Description: Drug dosing and blood sampling as per the protocol
Study NCT01680198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracalcitol
Description: Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
Study NCT00330187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Description: Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
Study NCT00330187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
Study NCT00330187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.
Study NCT00330187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.
Study NCT00330187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
Study NCT00330187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
Study NCT01196559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine and Gemcitabine
Description: Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle
Study NCT01568203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 579
Description: 3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
Study NCT01568203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo control for AMG 579 at each dose level